¼¼°è Ç×°£Áú¾à ½ÃÀå : ¼¼´ëº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°
Antiepileptic Drugs Market, By Generation, By Route of Administration (Oral, Intravenous, Others ), By Distribution Channel, By Geography
»óǰÄÚµå : 1378606
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2023³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è Ç×°£Áú¾à ½ÃÀåÀº 2023³â¿¡´Â 70¾ï 1,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2030³â¿¡´Â 88¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß(2023-2030³â) ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR)Àº 3.3%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁس⵵ 2022³â 2023³â ½ÃÀå ±Ô¸ð 70¾ï 1,000¸¸ ´Þ·¯
°ú°Å µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030³â
¿¹Ãø ±â°£ÀÇ CAGR 3.30% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 88¾ï 1,000¸¸ ´Þ·¯
±×¸² 1. Ç×°£Áú¾à ¼¼°è ½ÃÀå Á¡À¯À²(%), ¼¼´ëº°, 2023³â
Antiepileptic Drugs Market-IMG1

Ç×°£Áú¾àÀº °£Áú ¹ßÀÛÀ¸·Î °íÅë¹Þ´Â ȯÀÚ¿¡°Ô ó¹æµË´Ï´Ù. °£ÁúÀÇ ÁÖ¿ä Áõ»óÀº ¹ßÀÛÀÇ ¹Ýº¹À̸ç, ÀÌ´Â ³úÀÇ Àü±âÀû Ȱµ¿ÀÌ °©ÀÚ±â Æø¹ßÇÏ¿© ÀϽÃÀûÀ¸·Î ³úÀÇ ±â´É¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀÔ´Ï´Ù. ¹ßÀÛ Áß¿¡´Â ¸öÀÌ ºÎµéºÎµé ¶³¸®´Â °Íµµ ÀÖ°í, ÀǽÄÀÌ ¾ø¾îÁö°Å³ª ÀÌ»óÇÑ °¨°¢À» ±â¾ïÇÏ´Â °Íµµ ÀÖ½À´Ï´Ù. Ç×°£Áú¾à¿¡´Â ´Ù¾çÇÑ ¾àÁ¦ Ŭ·¡½º°¡ ÀÖ¾î ÆíµÎÅë ¿¹¹æ, ½Å°æÀå¾Ö¼º ÅëÁõ, ½Ö±Ø¼º Àå¾Ö µî °£Áú ÀÌ¿ÜÀÇ Áõ»ó¿¡µµ »ç¿ëµÇµµ·Ï µÇ¾î ¿Ô½À´Ï´Ù. Ç× °£Áú ¾à¹°Àº 1¼¼´ë, 2¼¼´ë, 3¼¼´ëÀÇ 3¼¼´ë·Î ºÐ·ùµË´Ï´Ù. °¢ ¼¼´ë´Â ´Ù¸¥ »ç¾çÀ» º¸¿©ÁÝ´Ï´Ù. 1¼¼´ë¿¡´Â ºê·ÒÈ­¹°, Æä³ë¹Ù¸£ºñÅ», ÇÁ¸®¹Ìµ·, Ä«¸£¹Ù¸¶Á¦ÇÉ, 2¼¼´ë¿¡´Â Æä¸£¹Ù¸ÞÀÌÆ®, ¶ó¸ðÆ®¸®±ä, ·¹º£Æ¼¶ó¼¼Å½, ±âŸ, 3¼¼´ë¿¡´Â ¶óÄÚ»ç¹Ìµå, ¾Æ¼¼Æ®»ê¿¡½º¸®Ä«¸£¹ÙÁ¦ÇÉ, Ŭ·Î¹ÙÀá µîÀÌ Æ÷ÇԵ˴ϴÙ. 3¼¼´ë ¾à¹°Àº º¸±Þ·ü Áõ°¡¿Í ÀÌ·¯ÇÑ ¾à¹°ÀÇ Ã¤¿ë Áõ°¡·Î ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ¿ªÇÐ

Çõ½ÅÀûÀÎ ½Å¾àÀ» ½ÃÀå¿¡ ÅõÀÔÇϱâ À§ÇØ, ÁÖ¿ä ±â¾÷Àº ¾à»ç ½ÂÀΰú °°Àº À¯±âÀû À¯±âÀû Àü·«À» äÅÃÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ¼¼°èÀÇ Ç× °£Áú ¾à¹° ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 3¿ù, ¹ÙÀÌ¿ÀÀǾàǰȸ»çÀÎ UCB SA´Â 2¼¼ ÀÌ»óÀÇ ·¹³ì½º¡¤°¡½ºÅä ÁõÈıº(LGS)¿¡ ¼ö¹ÝÇÏ´Â °£Áú ¹ßÀÛÀÇ Ä¡·áÁ¦·Î¼­ ³»º¹¾× CIVÀÎ FINTEPLA(ÆæÇ÷ç¶ó¹Î)°¡ ¹Ì±¹ ½Äǰ ÀǾàǰ±¹(FDA)¿¡ ÀÇÇØ ½ÂÀεǾú½À´Ï´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. LGS´Â ¾à¹° ÀúÇ×¼º ¹ßÀÛÀ» Ư¡À¸·ÎÇÏ´Â ¼Ò¾Æ±â ¹ßº´ÀÇ ½É°¢ÇÑ ¹ß´Þ¼º °£Áú¼º ³úÁõÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°è Ç×°£Áú¾à ½ÃÀå : COVID-19 ¿µÇ⠺м®

Á¦5Àå ¼¼°è Ç×°£Áú¾à ½ÃÀå : ¼¼´ëº°(2018-2030³â)

Á¦6Àå ¼¼°è Ç×°£Áú¾à ½ÃÀå : Åõ¿© °æ·Îº°(2018-2030³â)

Á¦7Àå ¼¼°è Ç×°£Áú¾à ½ÃÀå : À¯Åë ä³Îº°(2018-2030³â)

Á¦8Àå ¼¼°è Ç×°£Áú¾à ½ÃÀå : Áö¿ªº°(2018-2030³â)

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¼½¼Ç

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Antiepileptic Drugs Market is estimated to be valued at US$ 7.01 billion in 2023, and is expected to reach US$ 8.81 billion by 2030, exhibiting a Compounded Annual Growth Rate (CAGR) of 3.3% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 7.01 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 3.30% 2030 Value Projection: US$ 8.81 Bn
Figure 1. Global Antiepileptic Drugs Market Share (%), By Generation, 2023
Antiepileptic Drugs Market - IMG1

Anti-epileptic drugs are prescribed for patients who suffer from seizures. The major symptom of epilepsy is repeated seizures, which are sudden bursts of electrical activity in the brain that temporarily affects the functioning of the brain. Some seizures causes the body to jerk and shake, while others cause problems such as loss of awareness or unusual sensations. Anti-epileptic drugs include a diverse class of medications that are increasingly used for conditions apart from epilepsy such as migraine prophylaxis, neuropathic pain, and bipolar disorder. Anti-epileptics are categorized in three generations as first generation, second generation and third generation. Each generation denotes a different specification. The first generation drugs includes Bromide, Phenobarbital, Primidone, and Carbamazepine, second generation drugs include Felbamate, Lamotrigine, Levetiracetam, and others, and third generation drugs includes Lacosamide, Eslicarbazepine Acetate, Clobazam and others. The third generation drugs are anticipated to register the highest CAGR over the foreascted period attributed to rise in the rise in penetration and increasing adoption of these drugs.

Market Dynamics

In order to bring new and innovative drugs to the market, key players are engaged in adopting organic organic strategies such as regulatory approval which is expected to drive the global anti-epileptic drugs market growth over the forecast period. For instance, in March 2022, UCB S.A, a biopharmaceutical company, announced that FINTEPLA (fenfluramine), a oral solution CIV had been approved in theU.S., by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients of age two years and older. LGS is a severe childhood-onset developmental and epileptic encephalopathy characterized by drug-resistant seizures.

Key features of the study:

Antiepileptic Drugs Market Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Antiepileptic Drugs Market - COVID-19 Impact Analysis

5. Global Antiepileptic Drugs Market, By Generation, 2018-2030, (US$ Bn)

6. Global Antiepileptic Drugs Market, By Route of Administration, 2018 - 2030, (US$ Bn)

7. Global Antiepileptic Drugs Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

8. Global Antiepileptic Drugs Market, By Region, 2018 - 2030, (US$ Bn)

9. Competitive Landscape

10. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â